Literature DB >> 16631458

Mechanisms leading to the development of hormone-resistant prostate cancer.

Susan Kasper1, Michael S Cookson.   

Abstract

Advanced and metastatic prostate cancers remain potentially lethal tumors. Although androgen deprivation therapy remains the most effective treatment, patients who progress to androgen independence die of their disease. This article focuses on the mechanisms by which hormone resistance develops, including the reactivation of androgen receptor during androgen deprivation therapy, the role of cancer stem cells, and the emergence of epithelial-mesenchymal transition cells, which have increased metastatic potential. It is through an enhanced understanding of these mechanisms that new therapies can be developed to combat this disease.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16631458     DOI: 10.1016/j.ucl.2005.12.010

Source DB:  PubMed          Journal:  Urol Clin North Am        ISSN: 0094-0143            Impact factor:   2.241


  17 in total

1.  Flavokawain B, a kava chalcone, induces apoptosis via up-regulation of death-receptor 5 and Bim expression in androgen receptor negative, hormonal refractory prostate cancer cell lines and reduces tumor growth.

Authors:  Yaxiong Tang; Xuesen Li; Zhongbo Liu; Anne R Simoneau; Jun Xie; Xiaolin Zi
Journal:  Int J Cancer       Date:  2010-10-15       Impact factor: 7.396

2.  Expression of Long-chain Fatty Acyl-CoA Synthetase 4 in Breast and Prostate Cancers Is Associated with Sex Steroid Hormone Receptor Negativity.

Authors:  Marie E Monaco; Chad J Creighton; Peng Lee; Xuanyi Zou; Matthew K Topham; Diana M Stafforini
Journal:  Transl Oncol       Date:  2010-04       Impact factor: 4.243

Review 3.  Frequent gene products and molecular pathways altered in prostate cancer- and metastasis-initiating cells and their progenies and novel promising multitargeted therapies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Mol Med       Date:  2011-05-20       Impact factor: 6.354

Review 4.  Novel therapies against aggressive and recurrent epithelial cancers by molecular targeting tumor- and metastasis-initiating cells and their progenies.

Authors:  Murielle Mimeault; Surinder K Batra
Journal:  Anticancer Agents Med Chem       Date:  2010-02       Impact factor: 2.505

5.  Down-regulation of androgen-receptor and PSA by phytochemicals.

Authors:  Sophie Chen; Jian Gao; H Dorota Halicka; Frank Traganos; Zbigniew Darzynkiewicz
Journal:  Int J Oncol       Date:  2008-02       Impact factor: 5.650

Review 6.  Functions of normal and malignant prostatic stem/progenitor cells in tissue regeneration and cancer progression and novel targeting therapies.

Authors:  Murielle Mimeault; Parmender P Mehta; Ralph Hauke; Surinder K Batra
Journal:  Endocr Rev       Date:  2008-02-21       Impact factor: 19.871

7.  The role of PTEN/Akt/PI3K signaling in the maintenance and viability of prostate cancer stem-like cell populations.

Authors:  Anna Dubrovska; Sungeun Kim; Richard J Salamone; John R Walker; Sauveur-Michel Maira; Carlos García-Echeverría; Peter G Schultz; Venkateshwar A Reddy
Journal:  Proc Natl Acad Sci U S A       Date:  2008-12-30       Impact factor: 11.205

8.  Prostate cancer cells tolerate a narrow range of androgen receptor expression and activity.

Authors:  Natalia D Tararova; Natalya Narizhneva; Vadim Krivokrisenko; Andrei V Gudkov; Katerina V Gurova
Journal:  Prostate       Date:  2007-12-01       Impact factor: 4.104

9.  Pathogenesis of prostate cancer and hormone refractory prostate cancer.

Authors:  J S Girling; H C Whitaker; I G Mills; D E Neal
Journal:  Indian J Urol       Date:  2007-01

10.  Enhanced sensitivity to androgen withdrawal due to overexpression of interleukin-6 in androgen-dependent human prostate cancer LNCaP cells.

Authors:  T Terakawa; H Miyake; J Furukawa; S L Ettinger; M E Gleave; M Fujisawa
Journal:  Br J Cancer       Date:  2009-10-20       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.